Survey of Ophthalmology
Volume 49, Issue 2, Supplement 1 , Pages S26-S35 , March 2004

24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial

References 

  1. The advanced glaucoma intervention study (AGIS) . 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000;130:429–440
  2. Asrani S, Zeimer R, Wilensky J. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134–142
  3. Brown B, Morris P, Muller C, et al.  Fluctuations in intra-ocular pressure with sleep, (I: time course of IOP increase after the onset of sleep). Ophthalmic Physiol Opt. 1988;8:246–248
  4. Brubaker RF. Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol. 2001;45(Suppl 4):S347–S351
  5. Brubaker RF. Flow of aqueous humor in humans. Invest Ophthalmol Vis Sci. 1991;32:3145–3165
  6. Brubaker RF, Schoff EO, Nau CB. Effects on aqueous dynamics of AGN 192024, a new ocular hypotensive agent. Am J Ophthalmol. 2001;131:19–24
  7. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology. 1996;103:138–147
  8. Collaborative Normal-Tension Glaucoma Study Group . Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487–497
  9. David R, Zangwill L, Briscoe D, et al.  Diurnal intraocular pressure variations: an analysis of 690 diurnal curves. Br J Ophthalmol. 1992;76:280–283
  10. Drance SM. The significance of the diurnal tension variation in normal and glaucomatous eyes. Arch Ophthalmol. 1960;64:494–501
  11. DuBiner H, Cooke D, Dirks M. Efficacy and safety of bimatoprost in patients with elevated IOP: a 30-day comparison with latanoprost. Surv Ophthalmol. 2001;45(Suppl 4):S353–S360
  12. Gandolfi S, Simmons ST, Sturm R, et al.  Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. The Bimatoprost Study Group 3. Adv Ther. 2001;18:110–121
  13. Grant WM: Clinical aspects of the outflow of the aqueous humour, in: Glaucoma, a Symposium. Oxon 1955, pp 126-46
  14. Hayreh SS, Zimmerman MB, Podhajsky P, Alward WLM. Nocturnal arterial hypotension and its role in optic nerve head ischaemic disorders. Am J Ophthalmol. 1994;117:603–624
  15. Higginbotham EJ, Schuman JS, Goldberg I. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002;120:1286–1293
  16. Konstas AG, Mantziris DA, Stewart WC. Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. Arch Ophthalmol. 1997;115:182–185
  17. Krag S, Andersen HB, Sorensen T. Circadian intraocular pressure variation with beta-blockers. Acta Ophthalmol Scand. 1999;77:500–503
  18. Larsson L-I. Intraocular pressure over 24 hours after repeated administration of latanoprost 0.005% or timolol gel-forming solution 0.5% in patients with ocular hypertension. Ophthalmology. 2001;108:1439–1444
  19. Liu JHK, Kripke DF, Hoffman RE. Nocturnal elevation of intraocular pressure in young adults. Invest Ophthalmol Vis Sci. 1998;39:2707–2712
  20. Liu JHK, Kripke DF, Twa MD, et al.  Twenty-four–hour pattern of intraocular pressure in the aging population. Invest Ophthalmol Vis Sci. 1999;40:2912–2917
  21. Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol. 1991;111:51–55
  22. Morikawa T, Yoshida M. A useful testing strategy in phase II trials: combined test of superiority and test of equivalence. J Biopharm Stat. 1995;5:297–306
  23. Noecker RS, Dirks MS, Choplin NT, et al.  A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55–63
  24. Orzalesi N, Rossetti L, Invernizzi T, et al.  Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000;41:2566–2573
  25. Parrish RK, Palmberg P, Sheu W-P. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator, multicenter study. Am J Ophthalmol. 2003;135:688–703
  26. Racz P, Ruzsonyi MR, Nagy ZT. Around-the-clock (circadian) intraocular pressure reduction with once-daily application of 0.005% latanoprost by itself or in combination with timolol. Arch Ophthalmol. 1996;114:268–273
  27. Reiss GR, Lee DA, Topper JE, Brubaker RF. Aqueous humor flow during sleep. Invest Ophthalmol Vis Sci. 1984;25:776–778
  28. Sacca SC, Rolando M, Marletta A. Fluctuations of intraocular pressure during the day in open-angle glaucoma, normal-tension glaucoma and normal subjects. Ophthalmologica. 1998;212:115–119
  29. Shedden A, Laurence J, Tipping R, Timoptic-XE 0.5% Study Group . Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: a six-month, double-masked, multicenter study. Clin Ther. 2001;23:440–450
  30. Shirakashi M, Iwata K, Sawaguchi S, et al.  Intraocular pressure-dependent progression of visual field loss in advanced primary open-angle glaucoma: a 15-year follow-up. Ophthalmologica. 1993;207:1–5
  31. Stewart WC, Day DG, Sharpe ED, et al.  Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost. Am J Ophthalmol. 1999;128:692–696
  32. Stewart WC, Kolker AE, Sharpe ED. Factors associated with long-term progression or stability in primary open-angle glaucoma. Am J Ophthalmol. 2000;130:274–279
  33. Weinreb RN. A rationale for lowering intraocular pressure in glaucoma. Surv Ophthalmol. 2001;45(Suppl 4):S335–S336
  34. Zeimer RC, Wilensky JT, Gieser DK. Presence and rapid decline of early morning intraocular pressure peaks in glaucoma patients. Ophthalmology. 1990;97:547–550

☆ A preliminary report of these findings was presented at the Annual Meeting of the American Academy of Ophthalmology, November 11–14, 2001; New Orleans, Louisiana. The study was managed by Ophthalmic Research Associates, a contract research organization, in association with Allergan, Inc. This study was sponsored by Allergan, Inc., Irvine, California.T. Walters, H. DuBiner, S. Carpenter and the investigators in the Bimatoprost Circadian IOP Study Group have no proprietary interests in the study medications or in Allergan, Inc. B. Khan and A. VanDenburgh are employees of Allergan, Inc.

PII: S0039-6257(03)00192-9

doi: 10.1016/j.survophthal.2003.12.017

Survey of Ophthalmology
Volume 49, Issue 2, Supplement 1 , Pages S26-S35 , March 2004

Article Tools

* Image Usage & Resolution